Cargando…

A case study of polypharmacy management in nine European countries: Implications for change management and implementation

BACKGROUND: Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug events, hospitalizations, and healthcare spending. This study aimed to address: what exists regarding polypharmacy management in the European Union (EU); why programs were, or were not, developed; an...

Descripción completa

Detalles Bibliográficos
Autores principales: McIntosh, Jennifer, Alonso, Albert, MacLure, Katie, Stewart, Derek, Kempen, Thomas, Mair, Alpana, Castel-Branco, Margarida, Codina, Carles, Fernandez-Llimos, Fernando, Fleming, Glenda, Gennimata, Dimitra, Gillespie, Ulrika, Harrison, Cathy, Illario, Maddalena, Junius-Walker, Ulrike, Kampolis, Christos F., Kardas, Przemyslaw, Lewek, Pawel, Malva, João, Menditto, Enrica, Scullin, Claire, Wiese, Birgitt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905890/
https://www.ncbi.nlm.nih.gov/pubmed/29668763
http://dx.doi.org/10.1371/journal.pone.0195232
_version_ 1783315325401432064
author McIntosh, Jennifer
Alonso, Albert
MacLure, Katie
Stewart, Derek
Kempen, Thomas
Mair, Alpana
Castel-Branco, Margarida
Codina, Carles
Fernandez-Llimos, Fernando
Fleming, Glenda
Gennimata, Dimitra
Gillespie, Ulrika
Harrison, Cathy
Illario, Maddalena
Junius-Walker, Ulrike
Kampolis, Christos F.
Kardas, Przemyslaw
Lewek, Pawel
Malva, João
Menditto, Enrica
Scullin, Claire
Wiese, Birgitt
author_facet McIntosh, Jennifer
Alonso, Albert
MacLure, Katie
Stewart, Derek
Kempen, Thomas
Mair, Alpana
Castel-Branco, Margarida
Codina, Carles
Fernandez-Llimos, Fernando
Fleming, Glenda
Gennimata, Dimitra
Gillespie, Ulrika
Harrison, Cathy
Illario, Maddalena
Junius-Walker, Ulrike
Kampolis, Christos F.
Kardas, Przemyslaw
Lewek, Pawel
Malva, João
Menditto, Enrica
Scullin, Claire
Wiese, Birgitt
author_sort McIntosh, Jennifer
collection PubMed
description BACKGROUND: Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug events, hospitalizations, and healthcare spending. This study aimed to address: what exists regarding polypharmacy management in the European Union (EU); why programs were, or were not, developed; and, how identified initiatives were developed, implemented, and sustained. METHODS: Change management principles (Kotter) and normalization process theory (NPT) informed data collection and analysis. Nine case studies were conducted in eight EU countries: Germany (Lower Saxony), Greece, Italy (Campania), Poland, Portugal, Spain (Catalonia), Sweden (Uppsala), and the United Kingdom (Northern Ireland and Scotland). The workflow included a review of country/region specific polypharmacy policies, key informant interviews with stakeholders involved in policy development and implementation and, focus groups of clinicians and managers. Data were analyzed using thematic analysis of individual cases and framework analysis across cases. RESULTS: Polypharmacy initiatives were identified in five regions (Catalonia, Lower Saxony, Northern Ireland, Scotland, and Uppsala) and included all care settings. There was agreement, even in cases without initiatives, that polypharmacy is a significant issue to address. Common themes regarding the development and implementation of polypharmacy management initiatives were: locally adapted solutions, organizational culture supporting innovation and teamwork, adequate workforce training, multidisciplinary teams, changes in workflow, redefinition of roles and responsibilities of professionals, policies and legislation supporting the initiative, and data management and information and communication systems to assist development and implementation. Depending on the setting, these were considered either facilitators or barriers to implementation. CONCLUSION: Within the studied EU countries, polypharmacy management was not widely addressed. These results highlight the importance of change management and theory-based implementation strategies, and provide examples of polypharmacy management initiatives that can assist managers and policymakers in developing new programs or scaling up existing ones, particularly in places currently lacking such initiatives.
format Online
Article
Text
id pubmed-5905890
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59058902018-05-06 A case study of polypharmacy management in nine European countries: Implications for change management and implementation McIntosh, Jennifer Alonso, Albert MacLure, Katie Stewart, Derek Kempen, Thomas Mair, Alpana Castel-Branco, Margarida Codina, Carles Fernandez-Llimos, Fernando Fleming, Glenda Gennimata, Dimitra Gillespie, Ulrika Harrison, Cathy Illario, Maddalena Junius-Walker, Ulrike Kampolis, Christos F. Kardas, Przemyslaw Lewek, Pawel Malva, João Menditto, Enrica Scullin, Claire Wiese, Birgitt PLoS One Research Article BACKGROUND: Multimorbidity and its associated polypharmacy contribute to an increase in adverse drug events, hospitalizations, and healthcare spending. This study aimed to address: what exists regarding polypharmacy management in the European Union (EU); why programs were, or were not, developed; and, how identified initiatives were developed, implemented, and sustained. METHODS: Change management principles (Kotter) and normalization process theory (NPT) informed data collection and analysis. Nine case studies were conducted in eight EU countries: Germany (Lower Saxony), Greece, Italy (Campania), Poland, Portugal, Spain (Catalonia), Sweden (Uppsala), and the United Kingdom (Northern Ireland and Scotland). The workflow included a review of country/region specific polypharmacy policies, key informant interviews with stakeholders involved in policy development and implementation and, focus groups of clinicians and managers. Data were analyzed using thematic analysis of individual cases and framework analysis across cases. RESULTS: Polypharmacy initiatives were identified in five regions (Catalonia, Lower Saxony, Northern Ireland, Scotland, and Uppsala) and included all care settings. There was agreement, even in cases without initiatives, that polypharmacy is a significant issue to address. Common themes regarding the development and implementation of polypharmacy management initiatives were: locally adapted solutions, organizational culture supporting innovation and teamwork, adequate workforce training, multidisciplinary teams, changes in workflow, redefinition of roles and responsibilities of professionals, policies and legislation supporting the initiative, and data management and information and communication systems to assist development and implementation. Depending on the setting, these were considered either facilitators or barriers to implementation. CONCLUSION: Within the studied EU countries, polypharmacy management was not widely addressed. These results highlight the importance of change management and theory-based implementation strategies, and provide examples of polypharmacy management initiatives that can assist managers and policymakers in developing new programs or scaling up existing ones, particularly in places currently lacking such initiatives. Public Library of Science 2018-04-18 /pmc/articles/PMC5905890/ /pubmed/29668763 http://dx.doi.org/10.1371/journal.pone.0195232 Text en © 2018 McIntosh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
McIntosh, Jennifer
Alonso, Albert
MacLure, Katie
Stewart, Derek
Kempen, Thomas
Mair, Alpana
Castel-Branco, Margarida
Codina, Carles
Fernandez-Llimos, Fernando
Fleming, Glenda
Gennimata, Dimitra
Gillespie, Ulrika
Harrison, Cathy
Illario, Maddalena
Junius-Walker, Ulrike
Kampolis, Christos F.
Kardas, Przemyslaw
Lewek, Pawel
Malva, João
Menditto, Enrica
Scullin, Claire
Wiese, Birgitt
A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title_full A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title_fullStr A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title_full_unstemmed A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title_short A case study of polypharmacy management in nine European countries: Implications for change management and implementation
title_sort case study of polypharmacy management in nine european countries: implications for change management and implementation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905890/
https://www.ncbi.nlm.nih.gov/pubmed/29668763
http://dx.doi.org/10.1371/journal.pone.0195232
work_keys_str_mv AT mcintoshjennifer acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT alonsoalbert acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT maclurekatie acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT stewartderek acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kempenthomas acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT mairalpana acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT castelbrancomargarida acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT codinacarles acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT fernandezllimosfernando acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT flemingglenda acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT gennimatadimitra acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT gillespieulrika acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT harrisoncathy acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT illariomaddalena acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT juniuswalkerulrike acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kampolischristosf acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kardasprzemyslaw acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT lewekpawel acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT malvajoao acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT mendittoenrica acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT scullinclaire acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT wiesebirgitt acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT acasestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT mcintoshjennifer casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT alonsoalbert casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT maclurekatie casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT stewartderek casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kempenthomas casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT mairalpana casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT castelbrancomargarida casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT codinacarles casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT fernandezllimosfernando casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT flemingglenda casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT gennimatadimitra casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT gillespieulrika casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT harrisoncathy casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT illariomaddalena casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT juniuswalkerulrike casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kampolischristosf casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT kardasprzemyslaw casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT lewekpawel casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT malvajoao casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT mendittoenrica casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT scullinclaire casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT wiesebirgitt casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation
AT casestudyofpolypharmacymanagementinnineeuropeancountriesimplicationsforchangemanagementandimplementation